Is the FDA banning peptides? What FDA has actually done
No FDA document found calls any peptide banned. What FDA does, and what the October 2026 HHS policy on six compounded peptides does and does not change.
Peptio Research
On this page8
None of the FDA documents opened for this page uses the word "ban" for any peptide. What they describe is four separate kinds of action. FDA approves some peptide drugs. It decides which bulk substances, meaning raw active ingredients, pharmacies may use to compound medicines. It publishes a list of bulk substances that "may present significant safety risks" in compounding 1. And it acts against firms that sell unapproved drugs or ship ingredients into the United States. Every one of those documents is directed at manufacturers, compounders, sellers or importers. None of them addresses whether an individual may possess a peptide, and this page draws no conclusion either way. In October 2026 FDA's parent department, HHS, said that for six peptides it does not intend to act against compounders who meet listed conditions. That is not an approval, and the HHS policy does not use the word "ban" either. State law and agencies other than FDA and HHS were not researched.
Approval and compounding are different things
An approved drug has been reviewed by FDA before it is sold. A compounded drug, made by a pharmacist for a patient, has not. FDA puts it plainly: "Compounded drugs are not FDA-approved." 2 In a March 2026 announcement of letters to telehealth firms it added: "This means the agency does not review their safety, effectiveness or quality before they are marketed." 3 The same release says compounded drugs "can be important for overcoming shortages or meeting unique patient needs", but that compounders "should not try to compound drugs in a way that circumvents FDA's approval process" 3. The letters it announced cited "making false or misleading claims regarding compounded GLP-1 products" 3. That is action over marketing claims, not a prohibition on compounding.
Two parts of federal law govern compounding. Section 503A covers pharmacies and physicians compounding for individual patients; section 503B created "a new, voluntary category of compounders known as outsourcing facilities" 2.
The 503A bulks list and its three categories
Under 503A, a pharmacist may compound from a bulk substance that meets a pharmacopeia standard, or is part of an approved drug, or "appears on a list developed by the Secretary through regulations" 4 (p. 2). That list is the 503A bulks list, and it is built by rulemaking, after consulting an advisory committee 4 (p. 3).
While the list is being built, FDA sorts nominated substances into three categories under an interim policy, set out in guidance dated January 2025. In FDA's words 4 (p. 8):
- Category 1: "These substances may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list."
- Category 2: "These substances were nominated with sufficient supporting information to permit FDA to evaluate them, and they may be eligible for inclusion on the 503A bulks list. However, FDA has identified significant safety risks relating to the use of these substances in compounding pending further evaluation and, therefore, does not intend to adopt the policy described for the substances in Category 1."
- Category 3: "These substances may be eligible for inclusion on the 503A bulks list but were nominated with insufficient supporting information for FDA to evaluate them."
The Category 1 policy is a statement of enforcement intent: FDA "does not intend to take action" against a pharmacy compounding with a Category 1 substance if conditions are met, "until a substance has been evaluated and is identified in a final rule" 4 (p. 13). The guidance describes itself as nonbinding: "guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited" 4 (p. 2). It also ends categorisation for anything nominated on or after January 7, 2025 4 (p. 12).
The only completed list decision found for this page is a final rule published on February 19, 2019. It placed six substances on the list and declined four 5. The six were Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide; the four declined were oxitriptan, piracetam, silver protein mild and tranilast 5. None of the ten is a peptide. FDA's policy page also records a proposed regulation issued in September 2019, which proposed to place five substances on the list and not to place 26 others, and says that "After considering public comments, the agency will issue a final regulation" 6. That proposal was not opened for this page. No final rule placing or excluding any peptide was found.
Category 2 and the "withdrawn" table
FDA's page on bulk substances that may present significant safety risks, current as of April 22, 2026, says such substances "have been placed in category 2 under the interim policies" 1. Its table dates several peptide entries to September 29, 2023: GHRP-2 and GHRP-6 under 503B, ipamorelin acetate under 503B, and kisspeptin-10 under 503A 1. For GHRP-6, FDA's stated concern is that compounded drugs "may pose risk for immunogenicity for certain routes of administration", meaning a risk of provoking an immune response, "due to the potential for aggregation and peptide-related impurities" 1. For kisspeptin-10, it says "FDA has no, or only limited, safety-related information for the proposed routes of administration" 1. These are FDA's stated concerns, not measured outcomes.
A second table on the same page lists substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators" 1. It includes BPC-157, TB-500, GHK-Cu, Melanotan II, MOTS-c, epitalon, Semax, Selank, DSIP (listed as emideltide), dihexa, CJC-1295, AOD-9604, thymosin alpha-1 and ipamorelin acetate, among others, and gives no dates 1. Ipamorelin acetate thus appears in both tables; the page does not explain why. FDA's guidance says that withdrawing a nomination does "not reflect a determination by FDA regarding the validity of the nomination", and that FDA "may continue to evaluate a substance at its discretion" afterwards 4 (p. 15). A withdrawn nomination is neither an approval nor a ban. The safety-risks page itself does not use the word "ban" 1. HHS's October 2026 policy says that the six substances it covers were in Category 2 until April 22, 2026, and that "neither the placement nor the removal changed" their status under section 503A 7 (pp. 5-10).
The advisory committee
Before deciding on the list, FDA consults the Pharmacy Compounding Advisory Committee. Its function, in FDA's notice, is "to provide advice and recommendations to FDA on regulatory issues" 8. The committee votes; FDA decides, through rulemaking.
At its October 29, 2024 meeting, FDA proposed that ipamorelin not be included on the list. The committee voted on ipamorelin (free base): "Yes: 0 No: 12 Abstain: 1", and on ipamorelin acetate by the same count 9 (pp. 7-8). On kisspeptin-10 the result was "Yes: 0 No: 11 Abstain: 0" 9 (p. 8).
On December 4, 2024, FDA made the same proposal for CJC-1295, AOD-9604 and thymosin alpha-1 10. For CJC-1295 (free base) the vote was "Yes: 0 No: 13 Abstain: 0"; for CJC-1295 acetate, "Yes: 1 No: 12 Abstain: 0"; and for each of the three DAC forms, 0 yes, 13 no, 0 abstaining 10 (p. 7). For AOD-9604, voted on as a group, the result was "Yes: 0 No: 12 Abstain: 0" 10 (p. 8). For thymosin alpha-1 (free base) and thymosin alpha-1 acetate, each vote reads "Yes: 4 No: 17 Abstain: 0" 10 (pp. 8-9). In each case "yes" meant placing the substance on the list. These votes are advice. No final rule following them was found.
The committee met again on July 23 and 24, 2026, to consider BPC-157, KPV, TB-500 and MOTS-c on the first day, and emideltide (DSIP), Semax and epitalon on the second 11. FDA's meeting page, checked again on November 6, 2026, still posts no minutes, vote results or transcript 11. HHS's October 2026 policy states the direction, saying the committee voted in favour of each of the six it covers 7 (pp. 5-10). The counts were read here only second hand. A trade journal and a law firm both report that the committee voted to recommend six of the seven for the list, BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon, and voted against emideltide 12 13. Both give the BPC-157, KPV and TB-500 votes as 8 to 6 with one abstention, and emideltide as 6 in favour and 7 against with one abstention 12 13. The trade journal gives MOTS-c as 7 to 5 with two abstentions, and no count for Semax or epitalon 12. Neither report says whether a count covers the free base, the acetate or both. On these accounts the committee went against FDA's own briefing documents, which proposed not adding any of the seven 12 13.
A recommendation is not a listing. The law firm notes that "No peptide has been added to the FDA's list of bulk substances that pharmacies may use in compounding", and that FDA must decide whether to accept the votes and then go through a proposed and a final rule 13. Another meeting, on LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF, is listed for before the end of February 2027 14.
The October 2026 HHS policy
On October 30, 2026, the Federal Register carried a notice from the Secretary of Health and Human Services, FDA's parent department, announcing an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" 15. It had been under review at the Office of Information and Regulatory Affairs, part of the White House Office of Management and Budget, as an "Interim Access Policy for Compounding Using Certain Peptides", from October 14 to October 27, 2026 16.
The policy lists six substances: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 7 (p. 4). Emideltide is not among them. Until a final rule decides whether a substance goes on the 503A bulks list, HHS "does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician" compounding with one of the six "when all of the following circumstances are present" 7 (p. 2). There are ten 7 (pp. 2-4). Among other things, they cover the substance's identity and route limitations, its manufacture and testing, reporting to FDA, a label stating "This is a compounded drug product. Not for resale.", a single active ingredient in each product, and section 503A's patient-specific prescription requirement 7 (pp. 2-4). Appendix B names the acetate for five of the six and the free base for Semax, and limits each to stated routes 7 (pp. 5-10).
HHS gives its reasons. It says the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients" 7 (p. 2). For each substance it records that CDER, FDA's drug centre, "recommended against listing", then explains why it differs, pointing to newer manufacturing certificates, documented historical use and its own reading of the safety record 7 (pp. 5-10). That last point is a disagreement with FDA's drug centre about safety, not paperwork: HHS calls CDER's concerns "mechanistic rather than observed" for Semax (p. 8) and "inferential rather than observed" for TB-500 (p. 7) 7. Those are HHS's characterisations. FDA's briefings, and the entity pages here, set out what the record does and does not contain. The policy makes no finding that any of the six works, and it repeats that "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed." 7 (p. 1)
The notice sets the limits. It calls the document a "draft" policy, takes written comments for two weeks after publication, and says it "does not establish any rights for any person and is not binding on HHS or the public" 15. HHS "may revisit application of this interim policy (in whole or in part)" if, "among other things, a safety signal or product quality issue arises" 15. And "FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list" 15. So the policy adds nothing to the list. Neither document gives an effective date. The non-enforcement statement names pharmacies, federal facilities and physicians, not sellers of research-use products; of those products the policy says only that it "will discourage" use of "certain research-use-only peptides supplied by foreign manufacturers" 7 (p. 2). It does not address individuals possessing a peptide.
Enforcement against sellers
The documents found that act directly against peptide sales are warning letters, addressed to firms. A December 2024 letter to one seller noted products labelled "RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY", then said "evidence obtained from your websites establish that your products are intended to be drugs for human use" 17. It warned that failure to correct "may result in legal action including, without limitation, seizure and injunction" 17. An August 2026 letter to another firm made the same point: "Despite statements on your product labeling marketing your products "for research use only"" and "not for human or veterinary use," "evidence obtained from your website establishes that your products are intended to be drugs for human use." 18 A March 2026 letter said distribution of products labelled for "laboratory research purposes only" "violates sections 301(d) and 505(a) of the FD&C Act" 19. In these letters, a research-use label did not settle what the product was; FDA read intended use from the seller's own website.
FDA also uses import alerts, which "are used to protect consumers against products with a history of known violations" 20. A product under an alert "will be detained and refused unless the importer can overcome the appearance of the violation(s)" 20. Import alert 66-80, in the version published on October 9, 2026, covers "Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances" 21. FDA reports that of 48 GLP-1 ingredient sites it evaluated, "21% were noncompliant" 21. The alert concerns bulk ingredient shipments in that drug class. It is not an alert on all peptides.
What this means, and what it does not
For most of the peptides discussed online, the regulatory record found consists of interim categories, withdrawn nominations, advisory votes, a proposal not yet finalised, a draft, non-binding HHS enforcement policy for six compounded peptides, and enforcement against particular sellers. Saying FDA "banned" a peptide compresses all of that into a word FDA's own documents do not use.
The status of individual substances is on their own pages: BPC-157, TB-500, ipamorelin, CJC-1295, GHK-Cu, Melanotan II, MOTS-c, epitalon, Semax, Selank, DSIP and dihexa. The articles Is BPC-157 legal?, Are growth hormone peptides legal?, Is Melanotan 2 legal? and Is retatrutide FDA approved? go further on those questions. This page is a summary of FDA and HHS documents, with the July 2026 vote counts taken second hand from the two reports cited, and it is not legal advice.
Peptides covered
Research areas
Sources
- 1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 2. Human Drug Compounding Laws. U.S. Food and Drug Administration. 2024. View source(open access)
- 3. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (press announcement, March 3, 2026). U.S. Food and Drug Administration. 2026. View source(open access)
- 4. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry (January 2025). U.S. Food and Drug Administration. 2025. View source(open access)
- 5. List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act (final rule, 84 FR 4696). Federal Register (Food and Drug Administration). 2019. View source(open access)
- 6. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. 2026. View source(open access)
- 7. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. View source(open access)
- 8. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Federal Register (Food and Drug Administration). 2026. View source(open access)
- 9. Pharmacy Compounding Advisory Committee, October 29, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2024. View source(open access)
- 10. Pharmacy Compounding Advisory Committee, December 4, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2025. View source(open access)
- 11. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. View source(open access)
- 12. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC (The American Journal of Managed Care). 2026. View source(open access)
- 13. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. View source(open access)
- 14. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. View source(open access)
- 15. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526). Federal Register. 2026. View source(open access)
- 16. Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94), EO 12866 regulatory review. Office of Information and Regulatory Affairs, Office of Management and Budget. 2026. View source(open access)
- 17. FDA Warning Letter, MARCS-CMS 695607, December 10, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
- 18. FDA Warning Letter, MARCS-CMS 735063, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 19. FDA Warning Letter, MARCS-CMS 721805, March 31, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 20. Import Alerts. U.S. Food and Drug Administration. 2025. View source(open access)
- 21. Import Alert 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances (published 09/21/2026). U.S. Food and Drug Administration. 2026. View source(open access)